SCHEMBL7678361

SCHEMBL7678361

CCCCCCC(C(=O)O)c1cc(C)c(C(=O)c2ccc([N+](=O)[O-])cc2)n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
PNKP Q96T60 1/20 0.40
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
SRD5A2 P31213 1/20 0.38
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ABCB11 O95342 1/20 0.37
PTGS2 P35354 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
MGLL Q99685 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7680758 0.92 MAPT (0.45) ALDH1A1MAPTTDP1SLC6A2SLC6A4
SCHEMBL7680837 0.86 CNR2 (0.40) ALDH1A1KDM4EABCB11PTGS2
SCHEMBL7674913 0.85 ABCB11 (0.53) ALDH1A1MAPTTDP1KDM4EL3MBTL1
SCHEMBL7681159 0.82 MLYCD (0.38) SLC6A4SRD5A2ABCB11PTGS2SMN1; SMN2
SCHEMBL7678696 0.82 ABCB11 (0.38) ALDH1A1TDP1SLC6A3ABCB11PTGS2
SCHEMBL7680560 0.80 CYP1A2 (0.42) ALDH1A1HDAC3HDAC2SLC6A4MGLL
SCHEMBL7675385 0.78 ALDH1A1 (0.39) ALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL7675547 0.77 PTGS2 (0.42) ALDH1A1MAPTTDP1SLC6A2SLC6A3
SCHEMBL7680774 0.76 ABCB11 (0.57) ALDH1A1MAPTTDP1SRD5A2L3MBTL1
Valeric Acid SCHEMBL7693075 0.75 ABCB11 (0.48) ALDH1A1MAPTTDP1HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885MAPT 4570/4885TDP1 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.